模拟与rHuPH2020同时使用抗体的皮下药理动力学
Ryan P Nolan1, Marie A Printz1
1Halozyme Therapeutics, San Diego, California, USA.
难以预测皮下抗体的药理动力学 (PK). 使用临床数据和复合人体氨酶PH20 (rHuPH20) 的通用模型准确地表征抗体PK,从而能够更好地预测新疗法.
科学领域:
- 药理学 药理学是指药理学的学科.
- 生物技术是生物技术.
- 药物开发 药物开发
背景情况:
- 在人类中预测皮下 (SC) 抗体药理动力学 (PK) 是具有挑战性的,仅依靠临床数据.
- 复合人体氨酶PH20 (rHuPH20) 增强了大型治疗分子的SC传递.
- 一个广泛的PK数据库存在于与rHuPH20同时使用单克隆抗体.
研究的目的:
- 利用聚合的临床数据,开发一种用于SC抗体PK的通用建模框架.
- 为预测新抗体的预测模拟模型进行参数化,SC用rHuPH20.20给予SC.
- 建立优化SC剂量和时间表的初始条件.
主要方法:
- 从公开来源收集了10种SC与rHuPH20联合使用的抗体的PK数据.
- 适用于所有抗体的一致的两部分模型结构,具有所有抗体的目标结合动力学.
- 为每个抗体单独参数化了通用模型.
主要成果:
- 全面建模框架准确地描述了所有抗体的临床PK概况.
- 对吸收和生物可用性的SC PK参数在各种抗体和标中一致.
- 用rHuPH20进行下注射,使吸收率提高了30%左右,并维持或改善了生物可用性.
结论:
- 综合的临床数据和通用模型有效地描述了SC抗体PK与rHuPH20.
- 该模型提供可靠的参数值,用于预测新的SC抗体疗法的PK.
- 这种方法支持在药物开发过程中对SC剂量和时间表的明智决策.
更多相关视频
15:27Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms
Published on: April 17, 2017
11:09An HS-MRM Assay for the Quantification of Host-cell Proteins in Protein Biopharmaceuticals by Liquid Chromatography Ion Mobility QTOF Mass Spectrometry
Published on: April 17, 2018
相关概念视频
One-Compartment Open Model for IV Bolus Administration: General Considerations
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
Compartment Models: Single-Compartment Model
Compartment Models: Two-Compartment Model
Two-Compartment Open Model: IV Bolus Administration
The disparity between drug input and the sum of drug transfer rates between...
Routes of Drug Administration: Parenteral
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
Physiological Pharmacokinetic Models: Assumption with Protein Binding
